NOTES
3. Share capital
Share capital as at 30 June 2026 was EUR 30.7 million (EUR 30.7 million). The number of shares was as follows:
| Class A shares | Class B shares | Class C shares | Total | |
|---|---|---|---|---|
| 1 January 2025 | 76,631,101 | 73,507,818 | 3,396,276 | 153,535,195 |
| Conversion of class A to class B shares | -7,675 | 7,675 | ||
| Conversion of class C to class B shares | 839,599 | -839,599 | ||
| 30 June 2025 | 76,623,426 | 74,355,092 | 2,556,677 | 153,535,195 |
| 1 January 2026 | 76,549,801 | 74,428,717 | 2,556,677 | 153,535,195 |
| Conversion of class C to class B shares | 995,756 | -995,756 | ||
| 30 June 2026 | 76,549,801 | 75,424,473 | 1,560,921 | 153,535,195 |
Celox Holding AB owned 47,157,365 shares (47,157,365 shares) and 56.0% of the voting rights (56.0%).
The number of shares used to calculate the basic earnings per share was 151,656,945 (150,710,953) for the quarter and 151,319,606 (150,426,516) for the first half. The number of shares used to calculate the diluted earnings per share was 151,973,748 (150,978,791) for the quarter and 151,973,190 (150,979,081) for the first half.
C shares are held by the Company as treasury shares. The quota value was EUR 0.2 (EUR 0.2) per share.
Equity settled share-based programme
The five-year vesting period for Plan 2021 was completed on 29 April 2026. The performance conditions achieved corresponded to 8 performance shares for each share right. The EBITDA annual growth rate (CAGR) calculated on the basis of the Group’s financial statements for 2020 and 2025 was 18.6%. Refer to note 8 in the annual report 2025 for more information.
Medicover compensated the participants for the dividends paid during the duration of the programme by increasing the number of shares. In the quarter, 995,756 class C shares were converted to class B shares and distributed to the participants.